Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.Milind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|Journal of Clinical Oncology|2021Cited by 86
A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.George A. Fisher, Amita Patnaik, Johanna C. Bendell et al.|Journal of Clinical Oncology|2020Cited by 53